Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Revtorpyk (gedatolisib) is a multi-target PI3K/AKT/mTOR (PAM) inhibitor for the treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), PIK3CA wild-type locally advanced or metastatic breast cancer
Our global logistics network ensures efficient and reliable delivery
Brchers S, Skibicka KP
A half-life greater than 5 hours results in a stable signal, enabling batch processing of many plates at once using the GSH-Glo Assay
Therefore, the lack of physical activity in depressed individuals exacerbates metabolic dysfunctions, creating a pathway to diabetes
US$ 22.58
US$ 27.33
US$ 22.07
US$ 27.22
US$ 26.76
US$ 29.43
US$ 26.02
US$ 22.54
